Pfizer Inc. [NYSE: PFE] disclosed that US FDA has provided the firm approval for PREVNAR 20 for the avoidance of persistent disease and pneumonia triggered by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. It has been revealed that the U.S. CDC Advisory Committee on Immunization Practices (ACIP) is anticipated to organize a meeting in October to debate and revise recommendations about the safe and suitable use of pneumococcal vaccines in adults.
Furthermore, the authorization of the FDA for PREVNAR is a major step in the battle to help tackle the load of pneumococcal disease. It includes pneumonia in adults and broadens global protection against more disease-causing serotypes than any other pneumococcal conjugate vaccine.
Shares of Pfizer Inc. [NYSE: PFE] plunged 0.36% as it lost -0.14 during the trading session of Tuesday. The firm has recorded a trading volume of 18.85 million as compared to the average volume of 27.71 million during the trading session of Tuesday. In the past 52-weeks of the trading session, the share of the firm fluctuated between the 52-week low and high range of $29.96 and $43.08 from its 52-week low and high range, respectively. Pfizer has a total market capitalization of $216.47 billion at the time of writing.
In addition to this, more than half of all cases of aggressive pneumococcal disease (IPD) which include bacteremia and meningitis in adults ages 65 or older are due to the 20 serotypes in PREVNAR 20 in the US. These 20 serotypes are projected to cause up to 250,000 cases of IPD and community-acquired pneumonia and more than 10,000 deaths in adults ages 18 or older in the US.